Luis Gruberg, MD
Interventional Cardiology · East Setauket, NYNPI 1558462770
Payments from drug & device makers
Across 305 payments — averaging $1286.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$160K
- Johnson & Johnson$134K
- AstraZeneca$39K
- Chiesi USA, Inc.$25K
- Philips North America LLC$20K
- Amgen$6K
- plus $8K from 25 others
Across 3 payments — averaging $38,685 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$116K
What the payments were for
- Consulting fees$6,6754%
- Speaking & faculty fees$150,02087%
- Travel & lodging$4,4063%
- Food & beverage$10,4936%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 30 | $160,082 |
| Johnson & Johnson | 127 | $133,545 |
| AstraZeneca | 13 | $39,238 |
| Chiesi USA, Inc. | 20 | $25,126 |
| Philips North America LLC | 22 | $20,264 |
| Amgen | 4 | $5,789 |
| Alnylam Pharmaceuticals Inc. | 9 | $4,303 |
| Abbott | 15 | $699 |
| Abiomed | 11 | $587 |
| Novartis | 8 | $449 |
| Shockwave Medical, Inc | 4 | $334 |
| Boehringer Ingelheim | 3 | $265 |
| Biotronik Inc. | 4 | $258 |
| Boston Scientific | 3 | $171 |
| Cvrx, Inc. | 1 | $149 |
| Edwards Lifesciences | 2 | $128 |
| Heartflow, Inc. | 1 | $123 |
| Actelion Pharmaceuticals US, Inc. | 1 | $112 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $111 |
| AbbVie | 1 | $99 |
| Cardiva Medical, Inc. | 3 | $85 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $80 |
| Novo Nordisk | 3 | $58 |
| Lexicon Pharmaceuticals, Inc. | 2 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Penumbra, Inc. | 3 | $51 |
| Acist Medical Systems, Inc. | 1 | $44 |
| Teleflex LLC | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$131,314
- KENGREAL$24,659
- ONPATTRO$3,815
- BRILINTA$2,685
- (5027) Intact Vascular Und$524
- AMVUTTRA$368
- ENTRESTO$354
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$278
- Impella$260
- JARDIANCE$250
- Acticor 7 VR-T DX$216
- OPTIS$204
- ONYX FRONTIER$171
- COREVALVE EVOLUT R$170
- AMPLATZER Occluders$157
- Barostim Neo System$149
- SYNERGY$125
- FFRct$123
- Resolute$121
- Repatha$120
How this compares
$392,356 in reported general payments places this provider in the 85th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 18 | $29,251 |
| EliquisApixaban | 19 | $22,232 |
| BrilintaTicagrelor | 14 | $18,181 |
| Rosuvastatin Calcium | 40 | $658 |
| Metoprolol Succinate | 52 | $510 |
| Atorvastatin Calcium | 62 | $376 |
| Ezetimibe | 15 | $257 |
| Carvedilol | 43 | $217 |
| Furosemide | 34 | $181 |
| Clonidine Hcl | 13 | $179 |
| Lisinopril | 22 | $168 |
| Losartan Potassium | 19 | $134 |
| Nifedipine ErNifedipine | 11 | $124 |
| Hydralazine Hcl | 11 | $116 |
| Metoprolol Tartrate | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $133,545 | $29,25118 claims |
| AstraZenecaBrilinta | $39,238 | $18,18114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in East Setauket
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.